Promomed Group of Companies has started supplying Enoparin® to medical institutions

02.02.2022

Medicines

The first batch of the anticoagulant Enoparin®, registered by the company in the second half of 2021, was shipped from the Promomed Group's production site, the Biochemist plant. The drug, which is in demand to combat the complications of the new coronavirus infection, was first received by patients of Voronezh Clinical Emergency Hospital No. 1, Volgograd Clinical Hospitals No. 1 and No. 12.

Enoparin® is an effective anticoagulant recommended by the Ministry of Health of the Russian Federation to prevent a common complication of coronavirus infection – thrombosis and thromboembolism. These consequences are no less serious than the infection itself.

The main active ingredient of the drug, sodium enoxaparin, is isolated from the raw materials of low molecular weight heparins by modern biotechnological methods of purification and sterilization. The drug is used for the prevention and treatment of deep vein thrombosis, prevention of ischemic complications of unstable angina and myocardial infarction.

Deliveries of Enoparin are planned to all regions of the country.

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office